Tirzepatide Lowers Major Liver Outcomes in Cirrhosis
In compensated cirrhosis involving 816 matched pairs, tirzepatide associated with lower major adverse cardiovascular events at both time points and a lower 3-year major adverse liver outcomes rate of 8.3% versus 11.5% with a relative risk of 0.72, HCPLive reported.
The study showed no excess acute kidney injury or ascites-related outcomes in patients receiving the treatment. These results add real-world context to randomized data, including the phase 2 SYNERGY-NASH trial where tirzepatide improved metabolic dysfunction-associated steatohepatitis resolution compared with placebo.
Observational Design Limits Direct Comparisons
Observational designs cannot answer definitive questions, such as how tirzepatide compares directly with semaglutide, according to Alabbas. We need prospective studies,
Alabbas said, pointing to the necessity of further clinical investigation.
The research specifically focused on disease stage to evaluate comparative effectiveness. These findings could inform future clinical trials examining major adverse liver outcomes and major adverse cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.
Study Context: The findings were presented at The Liver Meeting 2026 held from November 5-9, 2026, in Denver, CO, by investigators including Alabbas M. Alabbas, A. Alnounou, and A.
Common Questions About the Study
What patient population was studied in the matched pairs?
The analysis evaluated 816 matched pairs of patients diagnosed with compensated cirrhosis and type 2 diabetes.
Did the treatment increase kidney risks?
No, the evaluation found no excess acute kidney injury or ascites-related outcomes associated with the therapy.
Where were these findings presented?
The data were presented at The Liver Meeting 2026 in Denver, Colorado, in November 2026.
Related reading